IFN therapies have been quite effective against hematological cancers, including hairy cell leukemia and chronic myelogenous leukemia but vary in efficacy against solid tumors, such as melanoma [reviewed in (222, 223, 241, 242)]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.